• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer Product Image

US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

  • Published: February 2011
  • Region: North America
  • 42 Pages
  • The Assessment Group

FEATURED COMPANIES

  • Amgen
  • Genentech/Roche
  • GlaxoSmithKline
  • Novartis
  • Onyx/Bayer
  • Pfizer
  • MORE

Survey of 119 US practicing medical oncologists and hematologist-oncologists

Overview

Treatment choices of 119 high-prescribing oncologists in response to clinical patient scenarios. Provides rich insights into specific treatment decisions, factors influencing their decisions, barriers to care, and confidence in managing these patients.

Series of clinical patient cases presented to the oncologists followed by clinical questions for open-ended responses on how they would treat and manage the patient and why. Data has been synthesized to show the highest reported responses, other responses, and direct quotes from the oncologists.

- Understand actual clinical decisions that are being made in real patient situations.
- Understand the most current practice patterns among high-prescribing oncologists.
- Understand what kinds of practice variations exist and why.

This report answers these questions:

- What treatment choices are being made first for advanced disease?
- What is the next choice upon further disease progression?
- How confident is the oncologist in this decision?
- What are the barriers to optimal patient care?
- Where READ MORE >

Executive Summary

Chapter 1: Introduction
Table 1. Treatment Options in Renal Cell Cancer
Table 2. Eligibility Criteria for Survey Participation
Figure 1.1 Gender of Survey Respondents
Figure 1.2 Years since Medical School Graduation
Figure 1.3 Practice Settings
Figure 1.4 Practices in NCI Cancer Centers
Figure 1.5 Geographic Settings
Figure 1.6 Survey Respondents by State’s Renal Cell Cancer Mortality
Figure 1.7 Number of Physicians in Practice Groups
Figure 1.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

Chapter 2: Treatment of Good to Moderate Prognosis Renal Cell Cancer
Figure 2.1 Initial treatment regimen chosen following surgery
Figure 2.2 Other therapeutic agents that would be considered appropriate
Figure 2.3 Treatment decision for medication toxicity
Figure 3.4 Second-line therapy treatment
Figure 2.5 Factors influencing treatment
Figure 2.6 Third-line therapy treatment
Figure 2.7 Most important barrier to optimal patient management
Figure 2.8 Confidence in managing this patient

Chapter 3: Treatment of Patient with Poor Prognosis Renal Cell Cancer
Figure 3.1 Appropriate treatment regimen
Figure 3.2 Treatment regarding metabolic and laboratory abnormalities
Figure 3.3 Treatment choice for progressive disease

Chapter 4: Treatment of Patient with Multiple Comorbidities
Figure 4.1 Management of patient with COPD
Figure 4.2 Choice of systemic therapy agent
Figure 4.3 Tests to monitor to evaluate increased fatigue with pazopanib
Figure 4.4 Next systemic treatment choice for progressive disease

Chapter 5: Treatment of Patient with Comorbidities: Solitary Kidney
Figure 5.1 Treatment regimen for patient with solitary kidney
Table 5.2 Treatment for disease progression
Figure 5.3 Factors influencing treatment decision
Figure 5.4 Most important barriers to treatment
Figure 5.5 Confidence in managing this patient

Chapter 6: Summary

Appendix A: Survey Instrument

- Novartis
- Genentech/Roche
- Onyx/Bayer
- Pfizer
- Pfizer
- GlaxoSmithKline
- Amgen

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos